While crizotinib is FDA-approved for the treatment of ALK-positive and ROS1-rearranged NSCLC as described above, there is a growing body of evidence that supports its use in MET exon 14 skipping mutations [61,64]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.